Lilly's Q2 Beat Widens Competitive Gap; Novo's Pricing Woes Persist

What happened

Eli Lilly and Novo Nordisk both reported Q2 2026 results in early August, and the contrast was stark, as highlighted by 24/7 Wall Street's 'One Winner' piece. Novo's Q2 showed only 3% constant-currency sales growth, with US obesity revenue up just 4% and injectable Wegovy sales down 22% due to lower realized prices, while oral Wegovy contributed DKK 3.1 billion but did not offset the decline. Lilly's results, though not detailed here, were evidently strong enough to earn the 'winner' label, reinforcing its momentum in the GLP-1 category. Novo raised full-year guidance but still expects sales and operating profit to decline 0-6% at CER, reflecting persistent price pressure and competitive threats. The master report already priced in these headwinds at a 11.6x P/E and 9.3x EV/EBITDA, but the new commentary suggests the competitive disadvantage may be more acute than previously modeled.

Implication

The base case of $52 (50% probability) now appears less certain as Lilly's competitive strength could accelerate price erosion and limit Novo's ability to convert oral scripts into reimbursed revenue. The bear case of $40 (25% probability) gains downside risk if PBMs and employers continue favoring Lilly products, eroding Novo's US obesity sales further. The bull case of $59 (25% probability) still hinges on CagriSema approval and zenagamtide progress, which are near-term catalysts but not guarantees. We advise trimming positions above $56 and consider adding only if the stock approaches $44, where the risk-reward improves based on cash generation. Monitor the September 21 CMD for concrete access economics and the Q4 CagriSema decision as pivotal events that could restore or further damage confidence.

Thesis delta

The original thesis that Novo's oral Wegovy can offset pricing pressure is now more challenged by the stark contrast in Q2 results, suggesting Lilly is pulling ahead faster than anticipated. While Novo's valuation remains attractive with strong free cash flow, the probability of the base case has decreased slightly, and we lower conviction from 3.5 to 3.0 and trim the fair value target to $50. The key uncertainty remains whether oral Wegovy can transition from self-pay to insured volume; without that, the stock may remain rangebound.